ImmunityBio stock climbed by nearly seven percent on January 21, pushing its year-to-date gain to roughly 200 percent following a three-week rally. Trading volume soared to approximately 96 million shares, nearly five times its three-month daily average, as short sellers grappled with covering positions that once comprised about 35 percent of the public float. Analysts estimate those investors now sit on approximately $500 million in unrealized losses. Since its 2015 IPO, ImmunityBio’s stock has declined around 80 percent from its initial offering, but the recent surge has lifted its market capitalization to about $6.4 billion. With an 80.4 percent gross margin, the company’s fundamentals in immunotherapy development for cancer and infectious diseases continue to draw speculative interest despite limited new clinical data this week.

In a Type B end-of-phase meeting with the U.S. Food and Drug Administration, ImmunityBio outlined next steps for its supplemental biologics license application for Anktiva in papillary non-muscle invasive bladder cancer. The company plans to submit additional clinical and manufacturing data within 30 days, focusing on long-term recurrence-free survival and optimized dosing schedules. A successful review could broaden the label for Anktiva, which already holds accelerated approval in other carcinoma indications. Investors are watching closely, as expanded approval would open a multi-hundred-million-dollar addressable market and potentially validate ImmunityBio’s strategy of pairing interleukin-15 superagonists with checkpoint inhibitors.